scroll down





Model Worker | Gao XingFa: Striving for Excellence and Innovation

From individuals to companies, a sense of responsibility signifies an unwavering drive to forge ahead. Gao XingFa, an entrepreneur, is the Chairman of Whale Pharmaceuticals, a fine chemical high-tech enterprise that integrates research, production, and sales. Following the development strategy of "Beijing R&D, Liu Chuan Production, Global Sales," Whale Pharmaceuticals aims to become a globally outstanding and leading pharmaceutical industrial company in China.



Gao XingFa, Chairman of Baiyin Jingyu New Pharmaceutical Co., Ltd.

Innovation is the inexhaustible driving force for sustainable business growth. Since the establishment of our R&D center in 2020, we have submitted three patent applications to the National Intellectual Property Administration, with three more in the pipeline. We have successfully transferred two patents, and we anticipate filing five to ten patent applications annually in the future.


[Chairman of Baiyin Jingyu New Pharmaceutical Co., Ltd. Gao XingFa]

"One of the products manufactured in our workshop is Dapagliflozin, a drug specifically for treating type 2 diabetes. It is a globally leading drug, exceptionally rare in terms of raw materials, with minimal side effects and rapid efficacy. We have a research institute in Beijing, where we have been conducting research and development for three to five years. We have already conducted small-scale trials in our laboratory and will soon commence final trials".


Dapagliflozin is an effective medication for diabetes treatment and is an innovative drug under the UK-based AstraZeneca. It can be used as a monotherapy to improve blood sugar control in adults with type 2 diabetes. Dapagliflozin is the first sodium-glucose co-transporter-2 (SGLT2) inhibitor to be marketed in China. Currently, no domestic companies are selling this product. It is the only diabetes drug included in medical insurance coverage, helping to lower blood sugar levels through sugar excretion in urine in addition to dietary and exercise improvements. It has the added benefit of weight reduction and is also safe for cardiovascular health.


According to the list of encouraged generic drugs published by the National Medical Products Administration's Department of Drug Policy and Basic Drug System, the active pharmaceutical ingredients of Empagliflozin and Dapagliflozin developed and produced by Whale Pharmaceuticals belong to the second batch of encouraged generic drugs. By addressing the shortage of clinically needed drugs and certain generic drugs, our efforts have a positive and proactive impact.

"As the company has grown, unity, innovation, and research and development have been crucial factors. We have a research and development team and institute based in Beijing," says Gao XingFa, Chairman of Baiyin Jingyuxin Pharmaceutical Co., Ltd. 



Gao XingFa, recognized as a Model Worker in Jingyuan County, has led Whale Pharmaceuticals in collaboration with several domestic pharmaceutical companies to accelerate the marketing and sales of innovative and generic drugs. This contributes to alleviating the suffering of patients and making a modest contribution to national healthcare reforms.


Zhang Renyue, an employee at Whale Pharmaceuticals, shares, "Mr. Gao is diligent and pragmatic in his work. Whenever we face challenging tasks, he is at the forefront, actively helping us solve problems. He cares deeply about his employees and serves as an exemplary role model."


Reported by Ma Zhenzhen and Duan Yuling from Jingyuan County Integrated Media Center.


Whale Group

Other Developments

Long-Term Partner Sumitomo Chemical Senior Executives Visit Whale Corp

On March 8, 2023, Jingyu Group received a visit from senior management of Sumitomo Chemical, a long-term important partner. Although the three-year pandemic has blocked offline meetings, it has never affected cooperation and communication between the two sides. Looking forward to closer and deeper cooperation between both parties in the future !



Whale Corp Engages in Collaborative Visit to Fudan University's School of Pharmacy

Recently, Jingyu Group Chairman Wang Fuping, General Manager Gao Ming and the core technical team were invited to the School of Pharmacy of Fudan University for visits and exchanges.



Whale Corp participated in the Beijing Tianjin Hebei Special Session of Inner Mongolia Investment Promotion and Project Signing Conference

On March 20, the government of the Inner Mongolia Autonomous Region held an investment promotion conference and project signing ceremony for the Beijing-Tianjin-Hebei region in Beijing. The conference held a signing ceremony for investment promotion projects. The heads of 78 companies from the Beijing-Tianjin-Hebei region successfully signed 80 projects with the autonomous region, involving new materials, equipment manufacturing, new energy, chemicals, agriculture and animal husbandry, modern service industries, and biomedicine 9 areas including energy conservation, environmental protection, and local-enterprise strategic cooperation, with a total agreed investment of 243.4 billion yuan.